In addition to treatment with optimized CAR-T therapy and previous chemotherapy regimens, as well as auto-HSCT (134, 135), novel anti-myeloma agents provide additional salvage options for R/R MM patients who have relapsed after anti-BCMA CAR-T cell therapy, including selinexor, carfilzomib, pomalidomide, monoclonal antibodies, and T cell redirecting bispecific antibodies (132–134, 136). Here, TNFRSF17 is linked to Miyoshi myopathy.